Cancers, Vol. 12, Pages 408: Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Cancers, Vol. 12, Pages 408: Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Cancers doi: 10.3390/cancers12020408
Authors:
Buonerba
Dolce
Iaccarino
Scafuri
Verde
Costabile
Pagliuca
Morra
Riccio
Ribera
De Placido
Romeo
Crocetto
Longo
Imbimbo
De Placido
Lorenzo
: Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic options. We performed a systematic review and a meta-analysis of randomized-controlled trials (RCTs) of first-line anti PD-1/PDL-1 agents vs. sunitinib, presenting efficacy data in the sub-group of sRCC patients. The systematic research was conducted on Google Scholar, Cochrane Library, PubMed and Embase and updated until 31th January, 2020. Abstracts from ESMO and ASCO (2010–2019) were also reviewed. Full texts and abstracts reporting about RCTs testing first-line anti-PD-1/ PD-L1 agents vs. sunitinib in RCC were included if sRCC sub-group analyses of either PFS (progression-free survival), OS (overall survival) or radiological response rate were available. Pooled data from 3814 RCC patients in the ITT (intention-to-treat) population and from 512 sRCC patients were included in the qua...
Source: Cancers - Category: Cancer & Oncology Authors: Buonerba Dolce Iaccarino Scafuri Verde Costabile Pagliuca Morra Riccio Ribera De Placido Romeo Crocetto Longo Imbimbo De Placido Lorenzo Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Statistics